EGRX Eagle Pharmaceuticals Inc.

-1.62  -2%
Previous Close 69.01
Open 68.87
Price To Book 5.46
Market Cap 1014618718
Shares 15,055,924
Volume 1,293,617
Short Ratio 10.77
Av. Daily Volume 215,240

SEC filingsSee all SEC filings

  1. 8-K - Current report 181068041
  2. 8-K - Current report 181045504
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999198
  4. 8-K - Current report 18996260
  5. 8-K - Current report 18943377

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial initiation announced December 7, 2017. Data due fall of 2018.
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Malignant hyperthermia - cancer
Phase 2 trial ongoing.
MDMA/meth intoxication
Phase 3 completion of enrollment announced August 30, 2018.
Exertional heat stroke (EHS)

Latest News

  1. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  2. Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market?
  3. Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
  4. Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
  5. Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference
  6. Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke
  7. Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  8. Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies
  9. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA
  10. Edited Transcript of EGRX earnings conference call or presentation 7-Aug-18 12:30pm GMT
  11. Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
  12. Eagle Pharmaceuticals: 2Q Earnings Snapshot
  13. Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
  14. Eagle Pharmaceuticals, Inc. to Host Earnings Call
  15. Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
  16. Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
  17. NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher
  18. Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

SEC Filings

  1. 8-K - Current report 181068041
  2. 8-K - Current report 181045504
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999198
  4. 8-K - Current report 18996260
  5. 8-K - Current report 18943377
  6. 8-K - Current report 18915129
  7. 8-K - Current report 18890931
  8. 8-K - Current report 18838766
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18823176
  10. 8-K - Current report 18820454